Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.
Conversion surgery
Nivolumab
R0 resection
Responder
Unresectable gastric cancer
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
21 Jul 2020
21 Jul 2020
Historique:
received:
25
04
2020
accepted:
10
07
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Patients with stage IV gastric cancer have a poor prognosis despite the recent development of multidisciplinary treatments that include chemotherapy. However, conversion surgery has emerged as a promising strategy to improve the prognosis in responders with unresectable gastric cancer after chemotherapy. Moreover, nivolumab is currently recommended as a third-line treatment in patients with unresectable advanced gastric cancer. However, there are few reports of conversion surgery after nivolumab in patients with stage IV gastric cancer. A 68-year-old woman complaining of nausea was diagnosed with stage I gastric cancer (T2N0M0). Although we planned gastrectomy with lymphadenectomy, multiple liver metastases were detected during the surgery. After staging laparoscopy, we diagnosed this patient as having stage IV unresectable gastric cancer, and we administered chemotherapy and immunotherapy for 39 months (first-line regimen: 6 courses of S-1 plus oxaliplatin; second-line regimen: 6 courses of ramucirumab plus paclitaxel; and third-line regimen: 20 courses of nivolumab). Although the liver metastases completely disappeared after the second-line chemotherapy, lung metastases and a rapid enlargement of the primary tumor were confirmed. Consequently, the patient received nivolumab at a dose of 3 mg/kg intravenously every 2 weeks, then a dose of 240 mg/kg intravenously every 2 weeks from September 2018. After 20 courses of nivolumab, the primary tumor dramatically shrank and the lung metastases disappeared. The patient had a partial primary tumor response to nivolumab. Therefore, the patient underwent laparoscopic distal gastrectomy with D2 lymph node dissection. The macroscopic examination of the resected specimen showed an ulcer scar in the primary tumor site. The pathological examination demonstrated no residual tumors and no lymph node metastases, and the histological response of the primary tumor was categorized as grade 3. The postoperative course was uneventful, and the patient is receiving nivolumab to control potential liver and lung metastases. Conversion surgery might help control tumor progression in responders after chemotherapy and immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with stage IV gastric cancer have a poor prognosis despite the recent development of multidisciplinary treatments that include chemotherapy. However, conversion surgery has emerged as a promising strategy to improve the prognosis in responders with unresectable gastric cancer after chemotherapy. Moreover, nivolumab is currently recommended as a third-line treatment in patients with unresectable advanced gastric cancer. However, there are few reports of conversion surgery after nivolumab in patients with stage IV gastric cancer.
CASE PRESENTATION
METHODS
A 68-year-old woman complaining of nausea was diagnosed with stage I gastric cancer (T2N0M0). Although we planned gastrectomy with lymphadenectomy, multiple liver metastases were detected during the surgery. After staging laparoscopy, we diagnosed this patient as having stage IV unresectable gastric cancer, and we administered chemotherapy and immunotherapy for 39 months (first-line regimen: 6 courses of S-1 plus oxaliplatin; second-line regimen: 6 courses of ramucirumab plus paclitaxel; and third-line regimen: 20 courses of nivolumab). Although the liver metastases completely disappeared after the second-line chemotherapy, lung metastases and a rapid enlargement of the primary tumor were confirmed. Consequently, the patient received nivolumab at a dose of 3 mg/kg intravenously every 2 weeks, then a dose of 240 mg/kg intravenously every 2 weeks from September 2018. After 20 courses of nivolumab, the primary tumor dramatically shrank and the lung metastases disappeared. The patient had a partial primary tumor response to nivolumab. Therefore, the patient underwent laparoscopic distal gastrectomy with D2 lymph node dissection. The macroscopic examination of the resected specimen showed an ulcer scar in the primary tumor site. The pathological examination demonstrated no residual tumors and no lymph node metastases, and the histological response of the primary tumor was categorized as grade 3. The postoperative course was uneventful, and the patient is receiving nivolumab to control potential liver and lung metastases.
CONCLUSIONS
CONCLUSIONS
Conversion surgery might help control tumor progression in responders after chemotherapy and immunotherapy.
Identifiants
pubmed: 32693806
doi: 10.1186/s12957-020-01954-0
pii: 10.1186/s12957-020-01954-0
pmc: PMC7374871
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179Références
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
World J Gastrointest Oncol. 2018 Nov 15;10(11):398-409
pubmed: 30487951
Ann Gastroenterol Surg. 2019 Oct 29;4(1):6-13
pubmed: 32021953
Ann Surg Oncol. 2015 Oct;22(11):3618-24
pubmed: 25663597
Gastric Cancer. 2019 Nov;22(6):1285-1293
pubmed: 31065878
BMC Cancer. 2018 Nov 15;18(1):1116
pubmed: 30442107
Gastric Cancer. 2020 May;23(3):510-519
pubmed: 31863227
J Surg Oncol. 2018 Jul;118(1):77-85
pubmed: 29878357
Lancet Oncol. 2009 Nov;10(11):1063-9
pubmed: 19818685
Gastric Cancer. 2016 Apr;19(2):329-338
pubmed: 26643880
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Immunother Cancer. 2018 Oct 11;6(1):106
pubmed: 30314524
Gastric Cancer. 2019 Mar;22(2):344-354
pubmed: 30506519
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Gastric Cancer. 2020 Feb 14;:
pubmed: 32060757
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancers (Basel). 2020 Jan 09;12(1):
pubmed: 31936512
Front Oncol. 2019 Nov 07;9:1158
pubmed: 31788445
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Ann Gastroenterol Surg. 2018 Jul 10;2(5):339-347
pubmed: 30238074
Oncology. 2020;98(5):273-279
pubmed: 32062663
Gastric Cancer. 2018 Mar;21(2):315-323
pubmed: 28616743
Ann Surg Oncol. 2015 Mar;22(3):787-92
pubmed: 25223927